| Zacks Company Profile for Exelixis, Inc. (EXEL : NSDQ) |
|
|
| |
| • Company Description |
| Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.
Number of Employees: 1,147 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $45.17 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 3,538,599 shares |
| Shares Outstanding: 272.71 (millions) |
| Market Capitalization: $12,318.23 (millions) |
| Beta: 0.28 |
| 52 Week High: $49.62 |
| 52 Week Low: $22.22 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
8.11% |
4.07% |
| 12 Week |
24.81% |
4.98% |
| Year To Date |
35.65% |
27.03% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Michael M. Morrissey - President and ChiefExecutiveOfficer
Stelios Papadopoulos - Chairman
Christopher J. Senner - Executive Vice President and ChiefFinancialOfficer
Mary C. Beckerle - Director
S. Gail Eckhardt - Director
|
|
Peer Information
Exelixis, Inc. (CORR.)
Exelixis, Inc. (RSPI)
Exelixis, Inc. (CGXP)
Exelixis, Inc. (BGEN)
Exelixis, Inc. (GTBP)
Exelixis, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 30161Q104
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
|
|
Share - Related Items
Shares Outstanding: 272.71
Most Recent Split Date: (:1)
Beta: 0.28
Market Capitalization: $12,318.23 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.61 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $2.36 |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: 9.00 |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: 21.16% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/25 |
|
|
|
| |
